Martin Reck, MD, PhD of LungenClinic Grosshansdorf, Grosshansdorf, Germany discusses roniciclib for extensive-disease small cell lung cancer (ED-SCLC). He explains that there are early results showing a chance for improved efficacy with this compound. Dr Reck then discusses a randomized Phase II trial (NCT02161419) investigating roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy for ED-SCLC. The primary endpoint was progression-free survival (PFS). However, no additional efficacy was shown with the addition of roniciclib to platinum-based chemotherapy. Further, there was also higher toxicity associated with the combination. Dr Reck explains that the signs of efficacy shown in the lab could not be translated to clinical practice; this group of patients remains difficult to treat. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.